STARLING ONCOLOGY INC
STLNNASDAQTrading Snapshot
- Day Range
- $6.16 – $6.25
- 52-Week Range
- $2.32 – $7.05
- Volume
- $2.98B
- Avg Volume
- $2.03B
- Shares Outstanding
- 100.0M
- Next Earnings
- Sep 9, 2026
Fundamentals Snapshot
- Annual Revenue
- $67M
- Last Q Revenue
- $18M
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- —
- Dividend Yield
- —
Why Investors Own STLN
- ✓High-growth profile — revenue up +15.6% YoY with expanding US Equity exposure.
- ✓Healthy economics — 51% gross margin and 14% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About STARLING ONCOLOGY INC
Starling Oncology, Inc., formerly The Oncology Institute, is a value-based oncology company advancing cancer care in the community setting. Founded in 2007, the company offers cutting-edge, evidence-based cancer treatments, including clinical trials and transfusions, to a large patient population. It operates as an integrated oncology platform serving patients, providers, and health plans across multiple markets with a focus on delivering high-quality, patient-centered care.
Otter Score Breakdown
ⓘAnalyst Price Target
ⓘLatest News & Updates
Starling Oncology shares are trading higher after the company reported a year-over-year decrease in Q2 loss per share and increase in sales results.
Starling Oncology Q2 EPS $(0.08) Up From $(0.15) YoY, Sales $161.282M Up From $119.802M YoY
Starling Oncology (NASDAQ:STLN) reported quarterly losses of $(0.08) per share. This is a 46.67 percent increase over losses of $(0.15) per share from the same period last year. The company reported $161.282 million in
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers AVITA Medical (NASDAQ:RCEL) stock rose 58.4% to $7.53 during Friday's regular session. The company's market cap stands at $146.1 million. As per the press release, Q2 earnings came out yesterday.
Starling Oncology, Inc. (STLN) Q2 2026 Earnings Call Transcript
Starling Oncology, Inc. (STLN) Q2 2026 Earnings Call August 6, 2026 5:30 PM EDTCompany ParticipantsMinh Merchant - Chief Legal OfficerDaniel Virnich - CEO...
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Doximity (NYSE:DOCS) stock rose 85.1% to $38.25 during Friday's pre-market session. The market value of their outstanding shares is at $3.7 billion. As per the news, the Q1 earnings report came out
The Oncology Institute, Inc. (STLN) Reports Q2 Loss, Tops Revenue Estimates
STARLING ONCOLO (STLN) delivered earnings and revenue surprises of -14.29% and +5.55%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?